This strategy identified the galactosyltransferase Core 1 synthase glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GALT1) as a promising biomarker of poor prognosis and a feasible treatment target for osteosarcoma. Here, C1GALT1 is linked to osteosarcoma.